Abstract
6-mercaptopurine (6-MP) is the first active metabolite inhibitor shown to suppress cancer cells. The aim of this study is to investigate the bioactivity of 6-MP derivatives and discover new anti-cancer agents. Four 6-mercaptopurine (6-MP) derivatives were synthesized and their anti-cancer activities were analyzed. All of the compounds showed anti-proliferative effects against HepG2 and A2780 cancer cells. Among the synthesized derivatives, 6-((naphthalen-2-ylmethyl)thio)-9H-purine (NMSP) which possessing a β-naphthalene, showed better anti-cancer activity than other compounds, with an IC50 value 6.09µg/mL. NMSP could induce S phase cell cycle arrest and apoptosis in HepG2 cells. Western blot analysis indicated that NMSP induced apoptosis is mitochondria-dependent. The novel 6-MP derivative discovered in this study is a promising drug candidate to be used as an anti-cancer agent.
Keywords: 6-mercaptopurine derivatives, synthesis, anti-cancer drugs, apoptosis, cell cycle, anti-proliferative.
Letters in Drug Design & Discovery
Title:Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Volume: 13 Issue: 6
Author(s): Yu-qin Ma, Xing Yan, Rong Du, Xiao-guang Yang, Yu-xin Li, Ying Gao and Wen-liang Li
Affiliation:
Keywords: 6-mercaptopurine derivatives, synthesis, anti-cancer drugs, apoptosis, cell cycle, anti-proliferative.
Abstract: 6-mercaptopurine (6-MP) is the first active metabolite inhibitor shown to suppress cancer cells. The aim of this study is to investigate the bioactivity of 6-MP derivatives and discover new anti-cancer agents. Four 6-mercaptopurine (6-MP) derivatives were synthesized and their anti-cancer activities were analyzed. All of the compounds showed anti-proliferative effects against HepG2 and A2780 cancer cells. Among the synthesized derivatives, 6-((naphthalen-2-ylmethyl)thio)-9H-purine (NMSP) which possessing a β-naphthalene, showed better anti-cancer activity than other compounds, with an IC50 value 6.09µg/mL. NMSP could induce S phase cell cycle arrest and apoptosis in HepG2 cells. Western blot analysis indicated that NMSP induced apoptosis is mitochondria-dependent. The novel 6-MP derivative discovered in this study is a promising drug candidate to be used as an anti-cancer agent.
Export Options
About this article
Cite this article as:
Ma Yu-qin, Yan Xing, Du Rong, Yang Xiao-guang, Li Yu-xin, Gao Ying and Li Wen-liang, Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives, Letters in Drug Design & Discovery 2016; 13 (6) . https://dx.doi.org/10.2174/1570180812666150821003536
DOI https://dx.doi.org/10.2174/1570180812666150821003536 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Current Chemical Biology Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy (Guest Editor: Dr. Felix Ruckert)]
Anti-Cancer Agents in Medicinal Chemistry Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Von Hippel-Lindau Disease
Current Molecular Medicine Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics